Scripps Research Institute spinout BlackThorn Therapeutics will use Yale's Gemini-Dot technology to identify drug targets for neurobehavioural disorders.
BlackThorn Therapeutics, a US-based neurobehavioural therapy spinout from Scripps Research Institute, has licensed research from Yale University’s School of Medicine.
The licence covers a technique dubbed Gemini-Dot which maps correlations between neuroimaging and gene expression in the brain to help identify drug targets and clinical populations.
BlackThorn is developing therapies for neurobehavioural conditions such as autism spectrum disorder, obsessive compulsive disorder and schizophrenia. It has a collaboration agreement in place with Yale’s Division of Neurocognition, Neurocomputation and Neurogenetics.
Gemini-Dot builds…
